#Biologics #Jordan #Amman #MS Pharma #Olayan Financing

MS Pharma Partners with Olayan Financing Company

AMMAN, Jordan, and RIYADH, Saudi Arabia - May 18, 2026 - In a significant development for the pharmaceutical sector in the MENA region, MS Pharma has announced a minority investment from Olayan Financing Company (OFC). This strategic alliance aims to enhance MS Pharma’s capabilities and accelerate its growth in a market rich with opportunities.

During the signing ceremony, MS Pharma’s President, Ghiath Sukhtian, expressed enthusiasm for this partnership, stating, "We are excited and honored to welcome OFC as our partners. Their global expertise in operations and investments, combined with their strong presence in Saudi Arabia, is sure to add significant value to MS Pharma and benefit all our stakeholders." This investment underscores the dedication of MS Pharma’s management team in providing quality pharmaceutical solutions and highlights the company’s potential as a leading player in the market.

The agreement allows MS Pharma to issue new equity shares in exchange for a substantial cash investment from OFC, resulting in OFC acquiring a minority stake in the company. This cash influx is expected to enhance MS Pharma’s financial standing and provide the flexibility needed to realize its ambitious growth plans in the MENA region. The investment will primarily support the expansion of MS Pharma's biosimilar portfolio and manufacturing capacity, strengthening its supply chain resiliency.

Kalle Kaend, CEO of MS Pharma, remarked, "This investment comes at a crucial time, enabling us to deepen our expertise in biological products and extend our reach in Saudi Arabia and the broader MENA region. We look forward to leveraging OFC’s extensive network in Saudi Arabia to achieve our ambitious goals while continuing to build a high-performing organization that generates long-term value for patients, partners, and employees."

Nabeel Al-Amudi, CEO of Olayan Financing Company, added, "MS Pharma has established itself as a leading pharmaceutical platform in the region with strong capabilities in generics and biologics. We are delighted to partner with the company at this critical juncture in its growth trajectory and look forward to supporting its continued expansion in Saudi Arabia and beyond."

The partnership builds upon MS Pharma’s leadership in the biosimilar space, particularly in Saudi Arabia, where the company’s biologics production facility was the first in the Kingdom to receive SFDA approval for manufacturing biologics. This year, MS Pharma aims to become the first local provider of biologics in the Saudi market, reinforcing its commitment to localization in line with Saudi Arabia's National Biotechnology Strategy and Vision 2030.

By expanding access to high-quality biological therapies throughout the region, MS Pharma is committed to upholding the highest regulatory and quality standards in collaboration with regional and international health authorities. Additionally, MS Pharma aims to deepen collaborations with global development and licensing partners, offering its manufacturing capabilities to support exports to international markets.

About MS Pharma

MS Pharma is a leading regional pharmaceutical company in the MENA area, specializing in the development, manufacturing, and distribution of a broad range of generic and biological therapies. Well-positioned for growth, the company operates five manufacturing facilities across Jordan, Algeria, and Saudi Arabia, including a newly inaugurated biologics plant serving the MENA market. Headquartered in Amman, Jordan, with administrative offices in Zug, Switzerland, MS Pharma employs over 2,000 individuals in 12 countries and is dedicated to improving patient access to affordable, high-quality medications.

For more information, visit www.mspharma.com.

About Olayan Financing Company (OFC)

Founded in 1947 by Suliman Saleh Olayan, OFC is a multinational conglomerate with a diverse portfolio of over 32 companies and global investments spanning Saudi Arabia, the Middle East, North Africa, Turkey, and India. As a long-term strategic investor, OFC’s investments include public equities, private equity, strategic partnerships, and real estate. OFC's workforce comprises more than 14,500 qualified professionals representing over 60 nationalities. In line with its commitment to making a positive long-term impact on society, the Suliman S. Olayan Foundation supports various initiatives in education, healthcare, and community development, contributing to the goals of economic diversification as outlined in Vision 2030. For more information, visit www.ofc.com.